New combo therapy aims to wipe out early anal cancer
NCT ID NCT06493019
Summary
This study is testing a new treatment approach for early-stage anal cancer. It combines an immunotherapy drug (pembrolizumab) with two chemotherapy drugs and radiation. The main goal is to see if this combination can completely eliminate detectable cancer and keep it from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Email: •••••@•••••
Contact
-
University of Maryland
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Email: •••••@•••••
Contact
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.